Quick Facts on Deprilan Uses

• Manages symptoms associated with major depressive episodes.
• Contributes to the treatment of generalized anxiety disorder.
• May be utilized to help manage obsessive-compulsive disorder (OCD).
• Is considered a relevant therapeutic option for social anxiety disorder (social phobia).

---

Deprilan is approved for use in the management of symptoms associated with major depressive episodes. It is considered to be a relevant treatment option for individuals experiencing this condition to promote overall mental well-being and support emotional balance. Clinical experience suggests that Deprilan may also be utilized in contributing to the treatment of several anxiety-related conditions.

Specifically, the medication is indicated for helping to manage the manifestations of generalized anxiety disorder. It is also used to address social anxiety disorder, also referred to as social phobia, to aid in reducing persistent symptoms. Furthermore, Deprilan may be applied to support patients with obsessive-compulsive disorder (OCD) and those experiencing panic disorder, which may include panic attacks.

Patients should be aware that it typically takes some time for the potential therapeutic effects to become evident. Consistent adherence to the treatment plan is important for achieving the intended benefits.

Eligibility for Deprilan (Selegiline)

Deprilan is officially permitted for use in adults ( 18 years) who do not present with any formal regulatory contraindications. Eligibility is strictly defined by prohibitions and limitations found in government-approved prescribing information.

Classification	Population/Condition
Contraindicated Populations	Patients with known hypersensitivity to selegiline. Patients concurrently taking other Monoamine Oxidase Inhibitors (MAOIs), specific antidepressants (SSRIs, SNRIs, most Tricyclics), or Opioid drugs (e.g., Meperidine/Pethidine). Patients with Pheochromocytoma.
Age-Related Rules	Pediatric Patients (under 18): Use is generally not established and not recommended due to a lack of safety and efficacy data. Older Adults ( 65 ): Permitted, but may require special monitoring.
Organ Function Restrictions	Severe Renal Impairment (CrCl <30 mL/min): Use is not recommended. Severe Hepatic Impairment (Child-Pugh >9): Use is not recommended; dose reduction is required for mild-to-moderate impairment.
Reproductive Status	Pregnancy & Lactation: Use is not recommended or restricted; potential risk to the fetus/infant is documented in official warnings.

These constraints establish absolute prohibitions and conditional requirements, defining who is ineligible for Deprilan under standard labeled conditions.

Interactions with other medicines and products

Deprilan (Selegiline) has officially documented interactions that result in significant administration restrictions. The primary interaction profile is defined by pharmacodynamic reinforcement, leading to severe reactions, and pharmacokinetic alterations affecting the drug's exposure.

Interaction Category	Specific Regulatory Restrictions
Formal Contraindications	Co-administration is strictly prohibited with Opioid drugs (e.g., Meperidine, Tramadol), Serotonergic agents (e.g., SSRIs, TCAs), other MAO Inhibitors (e.g., Linezolid), and Sympathomimetics (e.g., Pseudoephedrine).
Pharmacodynamic Risk	Combining with contraindicated substances can result in life-threatening events, including Serotonin Syndrome or Hypertensive Crisis. Use with Buspirone requires blood pressure monitoring due to the potential for substantial increases.
Pharmacokinetic Alterations	Oral Contraceptives (Gestodene/Ethinyl Estradiol) may officially increase Selegiline's bioavailability, and co-administration should be avoided. CYP3A4 Inducers may potentially decrease the plasma concentration of the medicine.
Timing Rules	A washout period of at least 14 days is required after discontinuing Deprilan before starting a contraindicated medication. A longer separation of at least 5 weeks is required after stopping Fluoxetine before starting Deprilan.
Substance Restrictions	Alcohol (Ethanol) and the herbal product St. John's wort are officially advised against or contraindicated. While the selective dose typically allows for no dietary Tyramine restrictions, caution is documented due to the risk of hypertensive reactions at non-selective doses.

The regulatory profile strictly defines the constraints of co-administration to mitigate these risks. Caution is also documented for use in patients with severe hepatic or renal dysfunction, as this may lead to higher systemic drug exposure.

Selective Irreversible MAO-B Inhibition

Deprilan's core action is defined by its molecular interaction as a mechanism-based inhibitor of the enzyme Monoamine Oxidase B (MAO-B). The active substance, Selegiline, forms a permanent, covalent bond with the enzyme's active site. This action leads to the irreversible inactivation of MAO-B, effectively removing the enzyme responsible for the metabolic breakdown, or catabolism, of certain neurotransmitters within the central nervous system (CNS).

---

Sustained Central Dopamine Conservation

The irreversible blockade of MAO-B prevents the destruction of dopamine in presynaptic nerve terminals and glial cells. This cessation of catabolism results in a sustained increase in available dopamine for release, which ultimately contributes to sustained dopaminergic neurotransmission in central pathways involved in physiological regulation. The duration of this effect is dictated by the time required for the body to synthesize new MAO-B enzyme molecules, rather than the drug’s plasma clearance.

---

Dose-Dependent Mechanistic Selectivity

This mechanism is subject to concentration constraints. While the drug is highly selective for MAO-B at low concentrations, this selectivity is lost at higher concentrations. Once the concentration threshold is exceeded, the drug also begins to inhibit MAO-A, thereby broadening the mechanistic effect to include the catabolism of monoamines, such as norepinephrine and serotonin, governed by the MAO-A pathway.

The instructions for Deprilan (Selegiline) define distinct administration procedures based on the oral dosage form, which includes the conventional tablet/capsule and the Orally Disintegrating Tablet (ODT). Both are taken via the oral route, but with different mandatory conditions.

Standard Dosage and Administration

The conventional oral form is typically administered at a total daily dose of 10 mg, which is often divided and taken as 5 mg doses twice a day. This conventional form is mandated to be taken with food (e.g., at breakfast and lunch) to support systemic exposure. In contrast, the ODT formulation is taken once daily beginning at 1.25 mg, and its administration is strictly food-restricted. The maximum dose for the ODT formulation is 2.5 mg per day.

Procedural and Population Rules

Patients using the ODT form must place the tablet on the tongue and avoid ingesting food or liquids for 5 minutes both before and after administration. The dosing protocol establishes a minimum of six weeks of initial therapy before considering a dose increase for the ODT form. Additionally, there are defined population-specific adjustments: the daily dose of the ODT must be reduced to 1.25 mg in patients with mild to moderate hepatic impairment. For patients receiving concurrent levodopa, the use protocol allows for the levodopa dosage to be gradually reduced by 10% to 30% within a few days of initiating selegiline.

Deprilan: Recent Clinical Evidence

Phase 3 Trials: Efficacy and Pain Reduction

Research has evaluated whether Deprilan was evaluated in studies involving moderate to severe pain by examining the reduction of pain scores.

• Study designs examined the time to onset of effect.
• Studies included patients who had not previously responded to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).
• Phase 3 clinical trials indicated that trial data reported differences compared to placebo across several efficacy endpoints, including the Brief Pain Inventory (BPI) and Patient Global Impression of Change (PGIC).
• Trial results in one study indicated an average reduction of 2 points on the 10-point Numerical Rating Scale (NRS) by week 4.

---

Safety Profile and Tolerability

The overall safety profile was reported through the reporting of adverse events in clinical trials.

• The most common adverse events, such as nausea and dizziness, were observed.
• The studies included reports of tolerability in elderly populations with mild renal impairment.
• The studies did not find evidence of a statistically significant increase in the incidence of serious adverse events compared to placebo.

---

Combination Therapy and Long-term Data

Research explored whether the combination of Deprilan and another drug affected the overall analgesic effect or the risk of respiratory depression.

• Deprilan's metabolism was examined in patients with severe liver disease.
• Evidence remains limited regarding the long-term effects of Deprilan beyond 12 weeks of use.
• Trials did not specifically evaluate the risk of developing substance use disorder (SUD) among participants.

Key Studies & References Long-term Safety and Efficacy Follow-up Study of Deprilan in Patients with Non-Malignant Chronic Pain

Common questions about Deprilan (FAQ)

Q: What happens in the body when Deprilan starts working?

Deprilan belongs to a class of drugs that works by blocking the action of an enzyme called Monoamine Oxidase B (MAO-B). Regulatory documents describe this action as a way to help increase the amount of the brain chemical dopamine that is available for release. This effect leads to sustained dopaminergic activity in the central nervous system.

Q: How long does it usually take to feel the initial effects of Deprilan?

Official information indicates that the enzyme-blocking action of Deprilan begins quickly. Inhibition of the targeted enzyme can be observed within 24 to 96 hours of starting treatment, depending on the specific dosage used. However, the timeframe for a patient to experience the full therapeutic effects may be longer.

Q: What information is available about taking Deprilan while pregnant or breastfeeding?

Official warnings state that there is currently insufficient data to determine the full risk of using Deprilan during pregnancy. For breastfeeding, the medication is not recommended due to the potential for serious adverse reactions in a breastfed infant.

Q: Can Deprilan affect blood sugar levels for people with diabetes?

While effects on blood sugar are not listed as a common adverse reaction in the primary product warnings, studies suggest that MAO inhibitors may influence glucose metabolism. Some case reports have noted that the medication has been associated with changes in insulin requirements or blood sugar levels.

Q: Is it safe to combine Deprilan with other psychiatric medications?

Regulatory documents state that co-administration is strictly prohibited with many classes of psychiatric medications, including most SSRIs, SNRIs, and Tricyclic Antidepressants. This is due to the potential for life-threatening events like Serotonin Syndrome or Hypertensive Crisis. The constraints established by regulatory guidance mandate that co-administration with any other psychiatric drug should be carefully evaluated.

Q: Does Deprilan affect a person's ability to drive or operate machinery?

The use of this drug can increase side effects such as dizziness, drowsiness, confusion, and difficulty concentrating. Official warnings include cautions against driving or operating machinery until a patient knows how the medication impacts their alertness and coordination.

Q: Can Deprilan be prescribed to adolescents or young adults?

Official labeling states that Deprilan is permitted for use in adults ( ge 18 years) who do not have contraindications. Use in individuals under 18 years is not recommended due to a lack of established safety and efficacy data in pediatric populations.

Q: Is it better to take Deprilan in the morning or at night?

The timing depends on the specific formulation. The orally disintegrating tablet (ODT) administration is typically indicated for once daily in the morning. The conventional tablet or capsule is generally described as being taken as a split dose, such as at breakfast and lunch.

Q: Can Deprilan make pre-existing fatigue or tiredness feel worse?

Regulatory documents list unusual tiredness or weakness as a possible adverse reaction. Additionally, side effects such as insomnia (difficulty sleeping) are also documented as possible adverse reactions.

Q: Why might someone experience increased anxiety when first starting Deprilan?

Anxiety is listed in the regulatory documents as a possible adverse reaction to the medication. This means that the drug has been associated with this symptom in some patients during clinical trials or post-marketing surveillance.

Q: Is it normal to feel no difference at all during the first week of taking Deprilan?

The timeframe for assessing the drug's effect is often longer than one week. Regulatory dosing protocols for some Deprilan formulations establish a minimum of six weeks of initial therapy before effectiveness is assessed or a dose adjustment is considered.

Q: What kind of monitoring is typically required while a patient is on Deprilan?

Official information states that blood pressure monitoring may be required frequently for patients receiving therapy to detect any evidence of a pressor response, which is a rapid increase in blood pressure.

Q: Are there any specific dietary restrictions mentioned in the official guidance for Deprilan?

Regulatory guidance includes statements against the use or limits on the consumption of alcohol (ethanol). Furthermore, official information includes caution statements against foods and beverages with high tyramine content, due to the documented risk of a hypertensive crisis, especially for patients taking higher doses.

Q: Is it normal to feel a change in appetite when starting Deprilan?

While a specific change in appetite is not listed as a common side effect, unusual weight loss is documented in regulatory materials as a possible adverse reaction.

Q: What happens if you stop taking Deprilan suddenly?

If the drug is stopped suddenly, official information indicates that some patients may experience withdrawal symptoms. These may include flu-like symptoms (such as sweating or chills), anxiety, agitation, and trouble sleeping.

How to Store and Dispose of Deprilan?

The storage and disposal of Deprilan (Selegiline hydrochloride) must follow the official requirements outlined in the product labeling to maintain stability and ensure safety.

---

Official Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, typically 25 C (77 F), with excursions permitted between 15 C and 30 C.
Protection	Keep away from excess heat, moisture, and light; do not store in areas like the bathroom.
Container	Keep the medication in the original container, tightly closed.
Child Safety	Keep Deprilan out of the sight and reach of children.

Disposal Instructions

To discard unused or expired Deprilan, the regulatory guidance prioritizes a drug take-back program. The medication must not be thrown into wastewater or released into the environment. If a take-back program is unavailable, dispose of the product in the household trash after mixing it with an undesirable substance.